| Trends in urological stone disease: a 5‐year update of hospital episode statistics H Heers, BW Turney BJU international 118 (5), 785-789, 2016 | 156 | 2016 |
| Fluid intake and dietary factors and the risk of incident kidney stones in UK Biobank: a population-based prospective cohort study TJ Littlejohns, NL Neal, KE Bradbury, H Heers, NE Allen, BW Turney European urology focus 6 (4), 752-761, 2020 | 106 | 2020 |
| Non-invasive detection of bladder tumors through volatile organic compounds: A pilot study with an electronic nose H Heers, JM Gut, A Hegele, R Hofmann, T Boeselt, A Hattesohl, ... Anticancer Research 38 (2), 833-837, 2018 | 33 | 2018 |
| CT Texture Analysis of Ex Vivo Renal Stones Predicts Ease of Fragmentation with Shockwave Lithotripsy HW Cui, W Devlies, S Ravenscroft, H Heers, AJ Freidin, RO Cleveland, ... Journal of endourology 31 (7), 694-700, 2017 | 25 | 2017 |
| Lymphoceles post-radical retropubic prostatectomy: a retrospective evaluation of epidemiology, risk factors and outcome H Heers, T Laumeier, PJ Olbert, R Hofmann, A Hegele Urologia internationalis 95 (4), 400-405, 2015 | 24 | 2015 |
| The immune checkpoint molecule CD200 is associated with tumor grading and metastasis in bladder cancer P Rexin, A Tauchert, J Haenze, H Heers, A Schmidt, R Hofmann, ... Anticancer Research 38 (5), 2749-2754, 2018 | 20 | 2018 |
| Diagnosis, treatment, and outcome of arterioureteral fistula: the urologist's perspective H Heers, C Netsch, K Wilhelm, A Secker, F Kurtz, P Spachmann, S Viniol, ... Journal of Endourology 32 (3), 245-251, 2018 | 17 | 2018 |
| Urolithiasis in Germany: trends from the National DRG Database H Heers, D Stay, T Wiesmann, R Hofmann Urologia Internationalis 106 (6), 589-595, 2022 | 16 | 2022 |
| Enfortumab vedotin in metastatic urothelial carcinoma: survival and safety in a European multicenter real-world patient cohort S Zschäbitz, N Biernath, T Hilser, A Höllein, F Zengerling, J Cascucelli, ... European Urology Open Science 53, 31-37, 2023 | 13 | 2023 |
| Frequency of microsatellite instability (MSI) in upper tract urothelial carcinoma: comparison of the Bethesda panel and the Idylla MSI assay in a consecutively collected, multi … F Kullmann, PL Strissel, R Strick, R Stoehr, M Eckstein, S Bertz, B Wullich, ... Journal of Clinical Pathology 76 (2), 126-132, 2023 | 13 | 2023 |
| Mrcc outcome in the treatment of metastatic renal cell carcinoma–a german single-center real-world experience M Schwab, R Hofmann, H Heers, A Hegele in vivo 32 (6), 1617-1622, 2018 | 12 | 2018 |
| Does visualisation during urethrocystoscopy provide pain relief? Results of an observational study J Koenig, S Sevinc, C Frohme, H Heers, R Hofmann, A Hegele BMC urology 15, 1-6, 2015 | 12 | 2015 |
| Alternative-and focal therapy trends for prostate cancer: a total population analysis of in-patient treatments in Germany from 2006 to 2019 L Flegar, A Zacharis, C Aksoy, H Heers, M Derigs, N Eisenmenger, ... World Journal of Urology 40 (7), 1645-1652, 2022 | 11 | 2022 |
| Prostate cancer tissues with positive TMPRSS2-ERG-gene-fusion status may display enhanced nerve density J Hänze, P Rexin, P Jakubowski, H Schreiber, H Heers, S Lingelbach, ... Urologic Oncology: Seminars and Original Investigations 38 (1), 3. e7-3. e15, 2020 | 10 | 2020 |
| Soluble PD-L1 in blood correlates positively with neutrophil and negatively with lymphocyte mRNA markers and implies adverse sepsis outcome M Derigs, H Heers, S Lingelbach, R Hofmann, J Hänze Immunologic research 70 (5), 698-707, 2022 | 9 | 2022 |
| Indications for nephron-sparing surgery: Analysis over a 13-year period in the context of changing guidelines PJ Olbert, M Maier, H Heers, A Hegele, R Hofmann Der Urologe 54, 804-810, 2015 | 9 | 2015 |
| Vinflunine in the treatment of upper tract Urothelial carcinoma–subgroup analysis of an observational study H Heers, P De Geeter, PJ Goebell, U Matz, W De Schultz, B Edlich, ... Anticancer Research 37 (11), 6437-6442, 2017 | 8 | 2017 |
| Assessing blood platelets as RNA biomarker source for prostate cancer J Hänze, P Jakubowski, H Heers, A Hegele, N Timmesfeld, R Hofmann, ... Biomarkers 21 (7), 653-659, 2016 | 8 | 2016 |
| Repeat Percutaneous Radiofrequency Ablation of T1 Renal Cell Carcinomas is Safe in Patients with Von Hippel–Lindau Disease J Wessendorf, A König, H Heers, AH Mahnken Cardiovascular and Interventional Radiology 44 (12), 2022-2025, 2021 | 7 | 2021 |
| Increased density of growth differentiation factor-15+ immunoreactive M1/M2 macrophages in prostate cancer of different gleason scores compared with benign prostate hyperplasia GA Bonaterra, A Schleper, M Skowronek, LS Kilian, T Rink, ... Cancers 14 (19), 4591, 2022 | 5 | 2022 |
